234 related articles for article (PubMed ID: 8874380)
1. Interphase cytogenetic analysis of serous ovarian tumors of low malignant potential: comparison with serous cystadenomas and invasive serous carcinomas.
Diebold J; Deisenhofer I; Baretton GB; Blasenbreu S; Suchy B; Schneiderbanger K; Meier W; Haas CJ; Löhrs U
Lab Invest; 1996 Oct; 75(4):473-85. PubMed ID: 8874380
[TBL] [Abstract][Full Text] [Related]
2. Interphase cytogenetic analysis of mucinous ovarian neoplasms.
Diebold J; Siegert S; Baretton GB; Suchy B; Meier W; Haas CJ; Löhrs U
Lab Invest; 1997 May; 76(5):661-70. PubMed ID: 9166285
[TBL] [Abstract][Full Text] [Related]
3. Numerical abnormalities of chromosomes 1, 11, 17, and X are associated with stromal invasion in serous and mucinous epithelial ovarian tumours.
Evans MF; McDicken IW; Herrington CS
J Pathol; 1999 Sep; 189(1):53-9. PubMed ID: 10451488
[TBL] [Abstract][Full Text] [Related]
4. Analysis of telomerase activity in ovarian cystadenomas, low-malignant-potential tumors, and invasive carcinomas.
Datar RH; Naritoku WY; Li P; Tsao-Wei D; Groshen S; Taylor CR; Imam SA
Gynecol Oncol; 1999 Sep; 74(3):338-45. PubMed ID: 10479490
[TBL] [Abstract][Full Text] [Related]
5. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
[TBL] [Abstract][Full Text] [Related]
6. Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions.
Emerson RE; Wang M; Liu F; Lawrence WD; Abdul-Karim FW; Cheng L
Int J Gynecol Pathol; 2007 Oct; 26(4):387-94. PubMed ID: 17885488
[TBL] [Abstract][Full Text] [Related]
7. Promoter hypermethylation profile of ovarian epithelial neoplasms.
Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
[TBL] [Abstract][Full Text] [Related]
8. Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas.
Osterberg L; Akeson M; Levan K; Partheen K; Zetterqvist BM; Brännström M; Horvath G
Cancer Genet Cytogenet; 2006 Jun; 167(2):103-8. PubMed ID: 16737908
[TBL] [Abstract][Full Text] [Related]
9. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
Meinhold-Heerlein I; Bauerschlag D; Hilpert F; Dimitrov P; Sapinoso LM; Orlowska-Volk M; Bauknecht T; Park TW; Jonat W; Jacobsen A; Sehouli J; Luttges J; Krajewski M; Krajewski S; Reed JC; Arnold N; Hampton GM
Oncogene; 2005 Feb; 24(6):1053-65. PubMed ID: 15558012
[TBL] [Abstract][Full Text] [Related]
10. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
McKenney JK; Soslow RA; Longacre TA
Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
[TBL] [Abstract][Full Text] [Related]
11. Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas.
Persons DL; Hartmann LC; Herath JF; Borell TJ; Cliby WA; Keeney GL; Jenkins RB
Am J Pathol; 1993 Mar; 142(3):733-41. PubMed ID: 8096121
[TBL] [Abstract][Full Text] [Related]
12. Cell proliferation in ovarian carcinoma: superior accuracy of S-phase fraction (SPF) by DNA labeling index versus flow cytometric SPF, lack of independent prognostic power for SPF and DNA ploidy, and limited effect of SPF on tumor growth rate.
Meyer JS; Gersell DJ; Yim S
Gynecol Oncol; 2001 Jun; 81(3):466-76. PubMed ID: 11371140
[TBL] [Abstract][Full Text] [Related]
13. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
[TBL] [Abstract][Full Text] [Related]
14. Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization.
Hauptmann S; Denkert C; Koch I; Petersen S; Schlüns K; Reles A; Dietel M; Petersen I
Hum Pathol; 2002 Jun; 33(6):632-41. PubMed ID: 12152163
[TBL] [Abstract][Full Text] [Related]
15. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
[TBL] [Abstract][Full Text] [Related]
16. Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma.
Staebler A; Karberg B; Behm J; Kuhlmann P; Neubert U; Schmidt H; Korsching E; Bürger H; Lelle R; Kiesel L; Böcker W; Shih IeM; Buchweitz O
Genes Chromosomes Cancer; 2006 Oct; 45(10):905-17. PubMed ID: 16845658
[TBL] [Abstract][Full Text] [Related]
17. Differences in p16 gene methylation and expression in benign and malignant ovarian tumors.
McCluskey LL; Chen C; Delgadillo E; Felix JC; Muderspach LI; Dubeau L
Gynecol Oncol; 1999 Jan; 72(1):87-92. PubMed ID: 9889036
[TBL] [Abstract][Full Text] [Related]
18. Allelic imbalance is not restricted to numerically abnormal chromosomes in epithelial ovarian tumours.
Evans MF; Herrington CS
J Pathol; 2001 Nov; 195(4):443-50. PubMed ID: 11745676
[TBL] [Abstract][Full Text] [Related]
19. Characteristic pattern of genetic aberrations in ovarian granulosa cell tumors.
Mayr D; Kaltz-Wittmer C; Arbogast S; Amann G; Aust DE; Diebold J
Mod Pathol; 2002 Sep; 15(9):951-7. PubMed ID: 12218213
[TBL] [Abstract][Full Text] [Related]
20. Numerical chromosomal aberrations in borderline, benign, and malignant epithelial tumors of the ovary: correlation with p53 protein overexpression and Ki-67.
Kohlberger PD; Kieback DG; Mian C; Wiener H; Kainz C; Gitsch G; Breitenecker G
J Soc Gynecol Investig; 1997; 4(5):262-4. PubMed ID: 9360232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
